IDEAYA Biosciences reports Monday after the close with short sellers pulling back from recent highs — yet the dominant shift heading into the print is a sharp rotation toward bullish options positioning.
The options market has turned notably more optimistic over the past two weeks. The put/call ratio has dropped to 0.77, roughly one standard deviation below its 20-day average of 1.19, reversing a period of heavy defensive hedging that saw the PCR peak near 2.3 in mid-May. That earlier defensiveness has been replaced by a call-heavy lean — a sign that options traders are positioning for a positive catalyst rather than guarding against a miss.
Short interest adds a constructive layer to that picture. Bears trimmed positions sharply over the past week, with short interest falling nearly 9% to 12.4% of free float. That remains a meaningful level for a clinical-stage biotech, but the direction of travel has shifted. The lending market is far from stressed: availability has expanded dramatically, now running at over 1,600% — meaning roughly 16 shares are available to borrow for every share already shorted — and the cost to borrow is negligible at 0.53%. There is no squeeze pressure here; shorts can hold or add without friction.
The analyst community is broadly aligned on the upside case. Eleven buy-equivalent ratings, a mean price target near $53 against a current price of $28.98, and a recent reiteration by Wedbush at $58 the day before the print all point toward a Street that sees the stock as substantially undervalued. Goldman Sachs is the outlier, holding a Neutral with a $35 target — a reminder that not everyone is convinced the pipeline justifies the implied re-rating. The bull case centres on IDEAYA's precision oncology pipeline, Fast Track and Breakthrough Designations, and a potential launch pathway opening in early 2027. Bears point to the absence of an approved product, ongoing cash burn, and the competitive pressures of the oncology drug market.
Past earnings reactions have been muted. The last four prints produced moves clustering between flat and down roughly 2% on the day, with five-day drifts similarly modest. Monday's release is therefore less a test of whether IDEAYA can shock the market and more a test of whether pipeline progress and cash runway guidance can close the gap between the stock's current price and the conviction embedded in eleven buy ratings.
See the live data behind this article on ORTEX.
Open IDYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
